Array Biopharma Inc.

Fredrik P Marmsäter

Qian Zhao

Joseph P Lyssikatos

James P Rizzi

George T Topalov

Mark C Munson

Julie Marie Greschuk

Stephen T Schlachter

Shelley Allen

John E Robinson

Mark Laurence Boys

Martha E Rodriguez

David A Mareska

Nicholas C Kallan

Erik James Hicken

Brad Newhouse

Weidong Liu

Robert Kirk DeLisle

April L Kennedy

Bryson Rast

D David Hennings

DavidD Hennings

Weidong Lui

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors

This invention provides compounds of Formula I wherein B, G, A, E, R, R, R, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Compounds of Formula I: in which A, B, R, R, R, R, R, RR, Rand Rhave the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1. 

Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors

Growing community of inventors

Boulder, CO, United States of America

Fredrik P Marmsäter